Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quantum Leap/Texas AG settlement

This article was originally published in The Tan Sheet

Executive Summary

Dallas-based Quantum Leap agrees to destroy nearly 15,000 bottles of human growth hormone-containing Regenesis and Lifespan products under a recent settlement with Texas Attorney General John Cornyn. Filed in Dallas County District Court, the Assurance of Voluntary Compliance also requires Quantum cease distributing the products without FDA approval, as well as pay $45,000 to the state for penalties and fees and refund consumers their purchase price. Genetically synthesized HGH is available only with FDA approval or a doctor's prescription. The National Institute on Aging issued a warning about the use of "anti-aging" hormones in 1997 (1"The Tan Sheet" April 7, 1997, p. 1)

You may also be interested in...



NIA warns public about DHEA, melatonin possible side effects, undiscovered risks.

LONG-TERM DHEA, MELATONIN USE DISCOURAGED BY NIA in a booklet titled "Can Hormones Reverse Aging?" being distributed by the National Institute on Aging. NIA, a component of the National Institutes of Health, is warning the public about using melatonin, DHEA (dehydroepiandrosterone) and other hormone supplements touted as having "anti-aging" effects in public service announcements airing on television nationwide. The PSAs feature a toll-free number that consumers can call to receive the free booklet.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel